NICE(UK) positive for Calquence + bendamustine and rituximab for untreated mantle cell lymphoma – AstraZeneca
NICE(UK): Acalabrutinib plus bendamustine and rituximab can be used, within its marketing authorisation, as an option for untreated mantle cell lymphoma in adults who are not eligible for… read more.
